Clinical Proteomics II

Program

• • Poster presentation
  • P-II-0618

  Proteomic characterization of Meningioma tissue and serum

  • Julieta Maria Medaglia (Freiburg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0619

  Quantitative proteomics identifies proteins and pathways involved in the progression from precancerous gastric lesions in a population of high-cancer gastric risk

  • Lizeth Mejia (Cali / CO)

   Clinical Proteomics
• • Poster presentation
  • P-II-0620

  Assessment of Hemoglobin-related clinical markers using volumetric absorptive microsampling and data-independent acquisition mass spectrometry

  • Valdemir Melechco Carvalho (São Paulo / BR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0621

  Harmonization of quantitative proteomics data collected across the international cancer proteogenome consortium

  • Gennifer E. Merrihew (Seattle, WA / US)

   Clinical Proteomics
• • Poster presentation
  • P-II-0622

  Integrative proteomic and AI-based histopathologic profiling reveals new prognostic subclusters in early-stage non-small cell lung cancer

  • Philipp Mertins (Berlin / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0623

  Understanding the proteome changes arising throughout 5-Fluorouracil chemoresistance development in colorectal cancer cells, with special focus on the methyl proteome

  • Isaac Micallef (Msida / MT)

   Clinical Proteomics
• • Poster presentation
  • P-II-0624

  ACR-2316: a potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity using Acrivon Predictive Precision Proteomics (AP3) for biological SAR

  • Georgia Mitsa (Lund / SE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0625

  Targeted quantitative proteomics of anticoagulated patients

  • Yassene Mohammed (Leiden / NL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0626

  Proteomic mapping of spatiotemporal dynamics in metastatic colorectal cancer

  • Vishnu Mohan (Rehovot / IL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0628

  The promise of the Orbitrap ASTRAL mass-spectrometer for proteomics analysis

  • Jean-Marc Monneuse (Lyon / FR)
  • Josephine Abi Ghanem (Lyon / FR)
  • Adrien Saliou (Villeurbanne / FR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0629

  Circulating plasma and salivary extracellular vesicles proteomes indicate prognostic signature in oral cancer

  • Carolina Moretto Carnielli (Campinas / BR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0630

  The forgotten success story of clinical proteomics: how autoantibodies discovered via proteomics tools are now key diagnostic biomarkers in neurology

  • Christian Moritz (Saint-Étienne / FR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0631

  Optimizing capivasertib response prediction in cancer: unveiling resistance mechanisms through precision proteomics

  • Neginsadat Mostolizadeh (Montreal / CA)

   Clinical Proteomics
• • Poster presentation
  • P-II-0632

  Quantification of Her2 expression in Her2-low tumors by targeted mass spectrometry

  • Negarsadat Mostolizadeh (Montreal / CA)

   Clinical Proteomics
• • Poster presentation
  • P-II-0633

  Serum proteomics of mother-infant dyads carrying HLA-conferred type 1 diabetes risk

  • Robert Moulder (Turku / FI)

   Clinical Proteomics
• • Poster presentation
  • P-II-0634

  Proteomic signatures of the eutopic endometrium of patients with deep bowel endometriosis

  • Arlindo Moura (Fortaleza / BR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0635

  Evaluation of new sample preparation methods associated with DIA analysis on Exploris 480 and Tims Tof SCP mass spectrometers to increase proteomic depth on plasma

  • Emmanuelle Mouton-Barbosa (Toulouse / FR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0636

  Why is the peripartum heart a substrate for dilated cardiomyopathy? A data driven investigation of molecular and cellular remodelling.

  • John Mulvey (Copenhagen / DK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0637

  Peptidomic analysis of cerebrospinal fluid samples reveals new biomarker candidates for amyotrophic lateral sclerosis

  • Besnik Muqaku (Ulm / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0638

  Differentially expressed protein biomarkers in early and advanced stage of young triple-negative breast cancer patients

  • Shamim Mushtaq (Karachi / PK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0639

  Plasma proteome profiling revealed altered levels of complements in the plasma of interverterbal disc degeneration patients

  • Sharon Miracle Nayagam (Coimbatore / IN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0640

  Plasma proteome profiling revealed altered levels of complements in the plasma of interverterbal disc degeneration patients

  • Sharon Miracle Nayagam (Coimbatore / IN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0641

  Comparative proteomic analysis of breast cancer and normal tissues with deep plasma profiling using the Mag-Net™ workflow

  • Adele Nel (Pretoria / ZA)

   Clinical Proteomics
• • Poster presentation
  • P-II-0642

  Protein-profiling of liquid biopsies for the differential diagnosis of pancreatic diseases

  • Thao Vi Nguyen (Luebeck / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0643

  Cell lines recapitulate the kinase activity profiles of colorectal tumor tissue and predict drug response

  • Rei Noguchi (Tokyo / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0644

  A proteomic skin disease atlas for accurate and rapid AI-driven clinical decision making

  • Thierry M. Nordmann (Planegg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0645

  A translational, high-throughput proteomics platform for the deep analysis of plasma samples

  • Estefanía Núñez (Madrid / ES)

   Clinical Proteomics
• • Poster presentation
  • P-II-0646

  ZenoSWATH proteomics and clustering analysis reveal different modulation patterns in fibroblasts from cystinosis patients by cysteamine

  • Ignacio Ortea (Oviedo / ES)

   Clinical Proteomics
• • Poster presentation
  • P-II-0647

  Pharmaco-proteogenomics for synovial sarcoma towards novel therapy

  • Julia Osaki (Tokyo / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0648

  The European cancer moonshot "Biobank" – the heart of cancer studies

  • Henriett Oskolás (Lund / SE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0649

  Predicting abdominal aortic aneurysms by combining mass spectrometry-based proteomics with clinical data

  • Nicolai Bjødstrup Palstrøm (Odense / DK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0650

  Proteome analysis with combined DIA and Glyco‑DIA approach of laser microdissected precursor lesions from pancreatobiliary cancer to improve early cancer diagnostics

  • Stella Maris Pauls (Duesseldorf / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0651

  Clinical proteomics elucidated the complex molecular mechanisms in the progression of dry eye syndrome with different severity levels: a step forward to personalized diagnosis

  • Natarajan Perumal (Mainz / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0652

  Development of a plasma proteomics methodology for biomarker discovery of immunocytokine therapy in Glioblastoma

  • Lucrezia Principi (Otelfingen / CH)

   Clinical Proteomics
• • Poster presentation
  • P-II-0653

  Saliva peptidome as source of possible biomarkers of salivary glands tumor

  • Michał Puchalski (Gdansk / PL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0654

  Time-resolved plasma proteomics predicts survival outcome of COVID-19 patients during hospitalization

  • Mauricio Quiñones-Vega (Rio de Janeiro / BR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0655

  Profiling of the pathophysiological mediators of a rare neurodegenerative disease, Friedreich's Ataxia (FRDA)

  • Jannatul Rafeya (Aachen / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0656

  Requirements and limitations for the preparation of targeted mass spectrometry assays enabling therapeutic drug monitoring

  • Yvonne Reinders (Dortmund / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0657

  Proteomics signature predictive of early biochemical progression and distant progression after stereotactic body radiotherapy in oligometastatic prostate cancer

  • Ombretta Repetto (Aviano / IT)

   Clinical Proteomics
• • Poster presentation
  • P-II-0658

  Comparative proteomic analysis of human ventricular tissue of over 100 patients undergoing heart transplantation

  • Ulrike Resch (Vienna / AT)

   Clinical Proteomics
• • Poster presentation
  • P-II-0659

  A high-throughput, in-depth investigation into the immunological effects of Lipopolysaccharide challenged mice in neat plasma on Orbitrap astral mass spectrometer

  • Jana Richter (Bremen / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0660

  Quality control for clinical proteomics

  • Svitlana Rozanova (Bochum / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0661

  An in-depth and high throughput plasma proteomics workflow powered by Orbitrap Exploris 480 mass spectrometer using multi nanoparticle-based workflow

  • Julian Saba (Winnipeg / CA)

   Clinical Proteomics
• • Poster presentation
  • P-II-0662

  Deep plasma proteomics profiling of healthy humans at two different stages of adulthood

  • Eduard Sabidó (Barcelona / ES)

   Clinical Proteomics
• • Poster presentation
  • P-II-0663

  Quantification of intra-amniotic inflammation in late preterm prelabor rupture of membranes associated with the response of amniotic fluid proteome

  • Michaela Sadibolova (Hradec Kralove / CZ)

   Clinical Proteomics
• • Poster presentation
  • P-II-0664

  Biomarker discovery through in-depth characterisation of the serum protein composition of infant victims of silent Abusive Head Trauma (AHT)

  • Tatjana Sajic (Lausanne / CH)

   Clinical Proteomics
• • Poster presentation
  • P-II-0665

  Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome and glycoproteom analysis

  • Yoshino Sakuma (Sagamihara-City / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0666

  Vasodilator-stimulated phosphoprotein acts as a potential plasma-derived exosomal protein marker for early detection of colorectal cancer

  • Juthaporn Sangwallek (Bangkok / TH)

   Clinical Proteomics
• • Poster presentation
  • P-II-0667

  Sample storage as pre-analytical factor on serum proteome quality

  • Thorben Sauer (Luebeck / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0668

  Profiling of the global proteome and the repertoire of N-termini of vitreous humor uncovers alterations of cell adhesiveness and extracellular matrix composition in rhegmatogenous retinal detachment

  • Diego Sbardella (Rome / IT)

   Clinical Proteomics
• • Poster presentation
  • P-II-0669

  Endoscope-based cold atmospheric Plasma (PLASMASKOP) as a novel therapeutic tool for the treatment of head and neck cancer

  • Christian Scharf (Greifswald / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0670

  Plasma proteome profiling reveals immunological dynamics in a longitudinal yellow FeverVaccination cohort

  • Alicia-Sophie Schebesta (Planegg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0671

  Enriching the diagnostic portfolio of the molecular tumor board with proteomics and phosphoproteomics of FFPE samples

  • Oliver Schilling (Freiburg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0672

  Phosphoproteomics adds value to treatment recommendations in molecular tumor boards

  • Annika Schneider (Freising / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0673

  Workflow for rapid proteome and phosphoproteome profiling of aging in mouse tissues

  • Felix Schneidmadel (Jena / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0674

  Tumour cell-induced platelet aggregation revealed different phenotypes between PDAC plasticity subtypes – A proteomic comparison between two pancreatic cancer cell lines

  • Katharina Schulz (Luebeck / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0675

  Exploring extracellular vesicle proteins as source of biomarkers for early detection of meningioma and predicting their therapeutic implications

  • Swati Sharma (New Delhi / IN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0676

  Search for novel diagnostic markers of chronic kidney disease in cats using proteome analysis

  • Momori Shimizu (Sagamihara-City / JP)
  • Hiroto Maeda (Tomakomai-city / JP)
  • Yoshio Kodera (Sagamihara-City / JP)
  • Kazuyuki Sogawa (Sagamihara-City / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0677

  Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome and proteome analysis

  • Noriaki Shinoda (Sagamihara-City / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0678

  Intra-sample three-point quantitative calibration using metabolically labelled QconCATs

  • Florian Christoph Sigloch (Bad Abbach / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0679

  Transmembrane glycoprotein GPNMB is a candidate predictive biomarker and potentially a therapeutic target in metastatic renal cell carcinoma

  • Jan Simonik (Brno / CZ)

   Clinical Proteomics
• • Poster presentation
  • P-II-0680

  FFPE tissue proteomics (LC-MS/MS): applications in diagnostic molecular pathology

  • Stephan Singer (Tuebingen / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0681

  Proteomics-driven biomarker discovery for M3913 in multiple myeloma xenograft models

  • Jasjot Singh (Darmstadt / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0682

  Proteomic remodeling of the heart following transplantation: the signature of cardiac allograft vasculopathy

  • Mikkel Skjoldan Svenningsen (Copenhagen / DK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0683

  Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome analysis

  • Kazuyuki Sogawa (Sagamihara-City / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0684

  The PATH biobank – fostering breast cancer research

  • Franziska Sommermeyer (Munich / DE)
  • Heinz Bodenmüller (Munich / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0685

  Analysis of women's health-related proteins in dried blood spots

  • William Stauch (Stockholm / SE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0686

  Identifying new immunotherapy targets for pediatric leukemia using cell surface proteome profiling.

  • Kelly Stecker (Utrecht / NL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0687

  Single Cell Deep Visual Proteomics (scDVP) of human hepatocytes in alpha-1 antitrypsin deficiency

  • Sophia Steigerwald (Munich / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0688

  MultiOmics landscape of pathotypes in rheumatoid arthritis – enroute to digital health using AI clinical diagnostics by nanoproteomics and AI based imaging diagnostics

  • Allan Stensballe (Gistrup / DK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0689

  An end-to-end (phospho)proteomics data analysis platform for precision oncology of 1000 prospective pan-cancer patients

  • Matthew The (Freising / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0690

  Insights from proteomic analysis in Crohn's disease

  • Johanna Thiery (Freiburg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0692

  Towards a noninvasive diagnosis of Peri-implantitis: proteomic analysis of Peri-implant crevicular fluid

  • Annika Topitsch (Freiburg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0693

  Comparative proteomic analysis of laser microdissected human glomeruli and tubules in IgA nephropathy

  • Yudai Tsuji (Aichi / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0694

  Proteogenomic profiling of mutated proteins in urine extracellular vesicles for non-invasive bladder cancer liquid biopsy

  • Koji Ueda (Koto-ku / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0695

  Early detection of liver cancer – the role of extracellular matrix proteins

  • Henry Unger (Heidelberg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0696

  Efficient Human Plasma Proteome Profiling at up to 240 Samples Per Day

  • Natalie Van Landuyt (Zwijnaarde / BE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0697

  Ultra-deep MS based plasma proteomics in a hand foot and mouth disease cohort

  • Iolanda Vendrell (Oxford / GB)

   Clinical Proteomics
• • Poster presentation
  • P-II-0698

  Multiplex mass spectrometry-based analysis of inflammatory proteins and their isoforms in serum samples of analog astronauts

  • Veronika Vidova (Brno / CZ)

   Clinical Proteomics
• • Poster presentation
  • P-II-0699

  Loss of SDHB manifests differently in the proteomes of neuroendocrine tumors and a tumor-derived cell line model hPheo-1

  • Ondrej Vit (Vestec / CZ)

   Clinical Proteomics
• • Poster presentation
  • P-II-0700

  Urinary proteome profiling of rat and human unveils biomarkers of LRRK2 activity

  • Duc Tung Vu (Munich / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0701

  Proteomic profiling of progressive multiple sclerosis patient brains reveals regional and cell-type protein differences related to disease processes

  • Henry Wang (Edmonton / CA)

   Clinical Proteomics
• • Poster presentation
  • P-II-0702

  Dynamic proteomic changes in tumor and immune organs reveal systemic immune response to tumor development

  • Yi Wang (Hangzhou / CN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0703

  TMT proteomics reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes

  • Sophia Weiner (Mölndal / SE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0704

  Proteomic profiling of IDH-wildtype glioblastoma reveals prognostic subtypes with matching abundances of semi-specific peptides in serum

  • Tilman Werner (Freiburg / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0705

  Monitoring disease status and treatment performance in multiple myeloma

  • Charissa Wijnands (Nijmegen / NL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0706

  dia-PASEF proteomic analysis of HNSCC tumor and stroma enriched sections from FFPE samples prepared with laser capture microdissection

  • Pierre-Olivier Schmit (Paris / FR)

   Clinical Proteomics
• • Poster presentation
  • P-II-0707

  Morphological and molecular profiling as a pilar of precision medicine: tailoring treatment in late-stage cancer patients

  • Nicole Woldmar (Malmö / SE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0708

  Leveraging the Orbitrap astral mass spectrometer to enable the analysis of low tissue content sample sources

  • Dylan Xavier (Westmead / AU)

   Clinical Proteomics
• • Poster presentation
  • P-II-0709

  Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes

  • He-Li Xu (ShenYang / CN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0710

  Comparative analysis of EV isolation method for urinary extracellular vesicles proteomics in cancer

  • Lijie Xu (Amsterdam / NL)

   Clinical Proteomics
• • Poster presentation
  • P-II-0711

  Proteomics-guided personalized therapy for advanced primary uterus diffuse large B-cell lymphoma: a case report

  • Xizhen Xu (Wuhan / CN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0712

  Reproducibility and reliability of protein quantity analyzed by DIA quantitative proteomics for urine biomarker discovery

  • Keiko Yamamoto (Niigata / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0713

  Urine bank in biofluid biomarker center and its usability for biomarker discovery

  • Tadashi Yamamoto (Niigata / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0714

  Discovery and validation of urine biomarkers for kidney nephron/site-specific damages by proteomics and immunoassay

  • Kengo Yanagita (Niigata / JP)

   Clinical Proteomics
• • Poster presentation
  • P-II-0715

  Unlocking biomarker discovery with novel high-throughput LC-MS workflows for translational research on an Orbitrap Astral mass spectrometer

  • Kevin Yang (San Jose, CA / US)

   Clinical Proteomics
• • Poster presentation
  • P-II-0717

  Discrepancies in proteomics data: autopsy versus fresh frozen samples

  • Xiaoke Yin (London / GB)

   Clinical Proteomics
• • Poster presentation
  • P-II-0718

  Proteomics identifies circulating TIMP-1 as a prognostic biomarker for diffuse large B-Cell Lymphoma

  • Xiaobo Yu (Beijing / CN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0719

  Structure-based protein biomarkers for early detection of breast cancer

  • Boris Zaslavsky (Cleveland, OH / US)

   Clinical Proteomics
• • Poster presentation
  • P-II-0720

  High-throughput peptidome profiling reveals Ischemic stroke-specific proteolysis changes in plasma

  • Andreas Zellner (Freising / DE)

   Clinical Proteomics
• • Poster presentation
  • P-II-0721

  Cross-platform proteomic profiling of plasma extracellular vesicles to identify biomarkers of malignant pulmonary modules

  • Liang ZHANG (Hong Kong / HK)

   Clinical Proteomics
• • Poster presentation
  • P-II-0722

  The molecular insights into the glomerulus injury and prognosis of patients with diabetic kidney disease by integrating proteomics and single-sell RNA sequencing

  • Tingting Zhao (nanjing / CN)

   Clinical Proteomics
• • Poster presentation
  • P-II-0723

  Proteomic and gene panel-based profiling of medullary thyroid cancer for prognosis prediction

  • Yan Zhou (Hangzhou / CN)

   Clinical Proteomics